Pulmonary Drug Delivery Devices Market
Pulmonary Drug Delivery Devices Market Scope:
Request Sample Report
Pulmonary Drug Delivery Devices Market Size and Growth
The Pulmonary Drug Delivery Devices market is rapidly growing, driven by advancements in technology and increasing respiratory diseases. The market was valued at approximately $30 billion in 2023, with a projected CAGR of 8% over the next five years. Demand for efficient inhalation therapies continues to rise, shaping the future landscape. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Boehringer Ingelheim GmbH
◍ Novartis AG
◍ GlaxoSmithKline
◍ AstraZeneca
◍ Teva Pharmaceutical Industries
◍ Merck
◍ MannKind
◍ Bristol-Myers Squibb
◍ Mylan N.V
◍ Omron Corp
◍ F. Hoffmann-La Roche
◍ 3M Healthcare
◍ Sunovion Pharmaceuticals
◍ Koninklijke Philips N.V
◍ Gerresheimer AG
◍ Bespak
◍ AptarGroup
The Pulmonary Drug Delivery Devices Market is competitive, with companies like Boehringer Ingelheim, Novartis, and AstraZeneca leading innovations in inhalers and nebulizers. They enhance market growth through robust R&D, strategic collaborations, and expanding product portfolios. Sales revenue figures include AstraZeneca ($37 billion) and Novartis ($51 billion), contributing to market expansion.
◍ SHL Group
Request Sample Report
Market Segmentation
By Application
Asthma
COPD
Cystic Fibrosis
Other
Request Sample Report
By Product
Dry Powder Inhaler
Metered Dose Inhaler
Nebulizer
Market Growth
Request Sample Report
$ 1.28 Billion
